Sangamo BioSciences | SGMO - Sales Revenues


Sangamo BioSciences reported $356K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Alterity Therapeutics Limited AUD 11.38K 10.23K Dec/2022
Amgen USD 9.9B 340M Dec/2025
Bayer EUR 9.66B 1.08B Sep/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Cipla INR 75.18B 710M Dec/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 1.89M 631K Sep/2025
CSL USD 3.54B 4.68B Jun/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Grifols EUR 2.18B 37.55M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
J&J USD 24.6B 610M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025